Injection of AD-MSCs reduced liver weight and steatosis by inhibiting pro-inflammatory genes including IL-6, TNF-α, and F4/80 expression (represented macrophage infiltration) and alleviating insulin resistance might via increasing IRS expression [15]. This evidence concerns the gene IL6 and Insulin resistance.